Success Metrics

Clinical Success Rate
82.6%

Based on 19 completed trials

Completion Rate
83%(19/23)
Active Trials
3(9%)
Results Posted
63%(12 trials)
Terminated
4(12%)

Phase Distribution

Ph not_applicable
6
18%
Ph phase_4
1
3%
Ph early_phase_1
1
3%
Ph phase_1
8
24%
Ph phase_2
17
52%

Phase Distribution

9

Early Stage

17

Mid Stage

1

Late Stage

Phase Distribution33 total trials
Early Phase 1First-in-human
1(3.0%)
Phase 1Safety & dosage
8(24.2%)
Phase 2Efficacy & side effects
17(51.5%)
Phase 4Post-market surveillance
1(3.0%)
N/ANon-phased studies
6(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.1%

19 of 26 finished

Non-Completion Rate

26.9%

7 ended early

Currently Active

3

trials recruiting

Total Trials

33

all time

Status Distribution
Active(5)
Completed(19)
Terminated(7)
Other(2)

Detailed Status

Completed19
Terminated4
Recruiting3
Withdrawn3
unknown2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
33
Active
3
Success Rate
82.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.0%)
Phase 18 (24.2%)
Phase 217 (51.5%)
Phase 41 (3.0%)
N/A6 (18.2%)

Trials by Status

terminated412%
recruiting39%
withdrawn39%
completed1958%
unknown26%
not_yet_recruiting26%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT07385937Not Applicable

Effectiveness of Genistein in Mild Cognitive Impairment

Not Yet Recruiting
NCT06689566Not Applicable

Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients

Recruiting
NCT07033767Phase 1

Exploring a Natural Solution for Childhood Obesity

Not Yet Recruiting
NCT06634108Phase 1

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

Recruiting
NCT06895954Not Applicable

The Clinical Study on Isoflavone Genistein in Restructuring the Gut Microbiota of Hyperlipidemia Patients

Completed
NCT01489813Phase 2

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Completed
NCT06501768Phase 1

Cardiovascular Genistein Therapy for Heart Failure Inflammation

Recruiting
NCT02624388Phase 2

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Terminated
NCT00244933Phase 2

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

Completed
NCT02766478Phase 2

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Terminated
NCT01982578Not Applicable

Genistein as a Possible Treatment for Alzheimer's Disease.

Completed
NCT00118040Phase 2

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Completed
NCT00376948Phase 2

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed
NCT00882765Phase 2

Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Withdrawn
NCT04105023Not Applicable

Genistein Stimulates Insulin Sensitivity Through Gut Microbiota

Completed
NCT01126879Phase 2

Genistein in Treating Patients With Prostate Cancer

Terminated
NCT00287690Phase 2

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Completed
NCT01985763Phase 1

Genistein in Treatment of Metastatic Colorectal Cancer

Completed
NCT00769990Phase 1

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

Withdrawn
NCT00290758Phase 2

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
33